Exp Ther Med. 2012 Sep;4(3):370-374. doi: 10.3892/etm.2012.632. Epub 2012 Jul 04.

Polysaccharide K suppresses angiogenesis in colon cancer cells.

Experimental and therapeutic medicine

Yoshiki Satoh, Takanori Goi, Toshiyuki Nakazawa, Youhei Kimura, Yasuo Hirono, Kanji Katayama, Akio Yamaguchi

PMID: 23181101 PMCID: PMC3503532 DOI: 10.3892/etm.2012.632

Abstract

The protein-bound polysaccharide K (PSK) is used as a non-specific immunotherapeutic agent for the treatment of colon cancer. Little research, however, has been conducted on its association with angiogenesis, which is a prognostic factor markedly correlated with hematogenous metastases. We therefore decided to investigate the action of PSK on angiogenic growth factors, angiogenesis inhibitors and angiogenesis in colon cancer cells. Reverse transcription-polymerase chain reaction (RT-PCR) was used to investigate changes in HIF-1α mRNA expression. PCR array was used to investigate changes in angiogenic growth factors and angiogenesis inhibitors, as well as the expression of related genes. Colon cancer cells were cultured with or without PSK for 48 h. The following day, cells were cultured for two days at 37°C in new complete media. The resulting culture medium was placed in the chamber of a tube formation system in order to investigate tube formation. Investigation of HIF-1α mRNA expression in colon cancer cell lines and in cells cultured under identical conditions with added PSK revealed a significant decrease in expression, as well as a decrease in angiogenic growth factors and related genes in PSK-treated colon cancer cell lines. By contrast, levels of angiogenesis inhibitors and related genes were higher in the PSK-treated colon cancer cell lines. Investigation of tube formation revealed that elongation was inhibited in the medium of the PSK-treated colon cancer cell lines in comparison to the medium of the non-treated colon cancer cell lines. PSK suppresses angiogenic growth factors and related genes, enhances angiogenesis inhibitors and related genes and ultimately suppresses angiogenesis in colon cancer cells.

References

1. Wiley Interdiscip Rev Syst Biol Med. 2010 May-Jun;2(3):336-361 - PubMed
2. Nat Rev Cancer. 2002 Jan;2(1):38-47 - PubMed
3. Br J Cancer. 2004 Mar 8;90(5):1003-10 - PubMed
4. Br J Cancer. 1998 Mar;77(6):998-1002 - PubMed
5. Br J Cancer. 1998;77(3):466-71 - PubMed
6. Br J Cancer. 1998 Nov;78(10):1379-84 - PubMed
7. Int J Oncol. 2012 Apr;40(4):960-4 - PubMed
8. Cancer Lett. 2006 Jun 8;237(1):10-21 - PubMed
9. J Surg Oncol. 2007 Dec 1;96(7):605-10 - PubMed
10. J Exp Clin Cancer Res. 1999 Mar;18(1):39-46 - PubMed
11. Biochem J. 2004 May 15;380(Pt 1):289-95 - PubMed
12. Cancer Biother Radiopharm. 2009 Feb;24(1):35-40 - PubMed
13. Cancer Metastasis Rev. 2007 Jun;26(2):333-9 - PubMed
14. Lymphokine Res. 1990 Winter;9(4):475-83 - PubMed
15. Cell. 1994 Oct 21;79(2):185-8 - PubMed
16. Cancer Metastasis Rev. 2007 Jun;26(2):281-90 - PubMed
17. Cell. 1996 Aug 9;86(3):353-64 - PubMed
18. Cancer Treat Rev. 1984 Jun;11(2):131-55 - PubMed
19. Curr Pharm Des. 2009;15(33):3839-43 - PubMed
20. Ann Surg Oncol. 2003 Aug;10(7):722-33 - PubMed
21. Cancer Immunol Immunother. 1990;31(5):261-8 - PubMed
22. Cancer Res. 2004 Mar 15;64(6):1906-10 - PubMed
23. Int J Cancer. 1997 Jan 27;70(3):362-72 - PubMed

Publication Types

• Journal Article